March 23, 2017

Say the word “cancer” and most people feel one thing: fear. That’s because, now more than ever, cancer seems to strike across such a broad range of categories — young, old, thin, fat, athletic, stationary and everything in between. With cancer’s prevalence, so too are its “cures,” many of which are wishy-washy in the name […]

by

Shutterstock photo (RTTNews.com) – AVEO Oncology ( AVEO ) has a couple of catalysts coming its way this year. A pre-planned interim futility analysis of phase III trial comparing investigational drug Tivozanib to approved drug Nexavar (sorafenib) in subjects with refractory advanced renal cell carcinoma, dubbed TIVO-3, is expected around mid-year 2017. Enrollment in the […]

by

Shutterstock photo (RTTNews.com) – AVEO Oncology ( AVEO ) has a couple of catalysts coming its way this year. A pre-planned interim futility analysis of phase III trial comparing investigational drug Tivozanib to approved drug Nexavar (sorafenib) in subjects with refractory advanced renal cell carcinoma, dubbed TIVO-3, is expected around mid-year 2017. Enrollment in the […]

by